Previous 10 | Next 10 |
IRVING, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant pol...
There is a potential development in the near horizon which could disrupt an entire industry. The industry that stands to be disrupted is the current treatment for ESRD (End-Stage Renal Disease) Dialysis. The potential development is a drug that might either delay or avoid ESRD coming from seve...
Reata Pharmaceuticals ( RETA ) is a late clinical stage biotechnology company with a chronic kidney disease therapy due to release results later this year. I last wrote about it in Reata Pharmaceuticals A Buy On Bardoxolone Data back in February 2018. The stock price then was $26.73 per sh...
Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Results Earnings Conference Call May 09, 2019, 08:00 AM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam ...
Reata Pharmaceuticals (NASDAQ: RETA ): Q1 GAAP EPS of -$0.98 beats by $0.02 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With Management Scheduled for Today, May 9, 2019 IRVING, Texas, May 09, 2019 (GLOBE NEWSWIRE) ...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with this Read more ...
IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that Colin Meyer, M.D., Reata’s Chief Medical Officer, will present a talk entitled “Translating the Novel Anti-Inflammatory ...
IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, May 9 th , 2019 at ...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...